The study aimed to explore the applicability of plasma phosphorylated tau (p‐tau)217 in identifying patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI) carrying Alzheimer's disease (AD) pathology in real‐world settings. The gene discussed is MAPT; the disease is Schnyder corneal dystrophy.